Performance of DAPT Score and ESC Criteria for Predicting Clinical Outcomes in Chinese Patients with Acute Coronary Syndrome

References

• Collet J, Thiele H, Barbato E, et al. 2020 ESC guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation. Eur Heart J. 2021;42(14):1289–1367.
   PubMed Web of Science ®Google Scholar
• Chan PYD, Ten BJ. Long-term residual cardiovascular risk after acute coronary syndrome: antithrombotic treatment options. Neth Heart J. 2022;30(1):38–46. doi:10.1007/s12471-021-01604-4
   PubMed Web of Science ®Google Scholar
• Mauri L, Kereiakes DJ, Yeh RW, et al. Twelve or 30 months of dual antiplatelet therapy after drug-eluting stents. N Engl J Med. 2014;371(23):2155–2166. doi:10.1056/NEJMoa1409312
   PubMed Web of Science ®Google Scholar
• Garratt KN, Weaver WD, Jenkins RG, et al. Prasugrel plus aspirin beyond 12 months is associated with improved outcomes after TAXUS liberté paclitaxel-eluting coronary stent placement. Circulation. 2015;131(1):62–73. doi:10.1161/CIRCULATIONAHA.114.013570
   PubMed Web of Science ®Google Scholar
• Bansilal S, Bonaca MP, Cornel JH, et al. Ticagrelor for secondary prevention of atherothrombotic events in patients with multivessel coronary disease. J Am Coll Cardiol. 2018;71(5):489–496. doi:10.1016/j.jacc.2017.11.050
   PubMed Web of Science ®Google Scholar
• Bonaca MP, Bhatt DL, Cohen M, et al. Long-term use of ticagrelor in patients with prior myocardial infarction. N Engl J Med. 2015;372(19):1791–1800. doi:10.1056/NEJMoa1500857
   PubMed Web of Science ®Google Scholar
• Bhatt DL, Steg PG, Mehta SR, et al. Ticagrelor in patients with diabetes and stable coronary artery disease with a history of previous percutaneous coronary intervention (THEMIS-PCI): a Phase 3, placebo-controlled, randomised trial. Lancet. 2019;394(10204):1169–1180. doi:10.1016/S0140-6736(19)31887-2
   PubMed Web of Science ®Google Scholar
• Connolly SJ, Eikelboom JW, Bosch J, et al. Rivaroxaban with or without aspirin in patients with stable coronary artery disease: an international, randomised, double-blind, placebo-controlled trial. Lancet. 2018;391(10117):205–218. doi:10.1016/S0140-6736(17)32458-3
   PubMed Web of Science ®Google Scholar
• Yeh RW, Secemsky EA, Kereiakes DJ, et al. Development and validation of a prediction rule for benefit and harm of dual antiplatelet therapy beyond 1 year after percutaneous coronary intervention. JAMA. 2016;315(16):1735–1749. doi:10.1001/jama.2016.3775
   PubMed Web of Science ®Google Scholar
• Veron-Esquivel D, Batiz-Armenta F, Cazares-Diazleal AC, et al. Validation of DAPT score for prolonged dual antiplatelet therapy in patients with acute myocardial infarction. Hell J Cardiol. 2019;60(5):296–302. doi:10.1016/j.hjc.2018.05.007
   PubMed Web of Science ®Google Scholar
• Kim M, Park KW, Lee HS, et al. The validation of the dual antiplatelet therapy score in East Asians receiving percutaneous coronary intervention with exclusively second generation drug-eluting stents. Catheter Cardiovasc Interv. 2021;98(3):E332–E341. doi:10.1002/ccd.29682
   PubMed Web of Science ®Google Scholar
• Yoshikawa Y, Shiomi H, Watanabe H, et al. Validating utility of dual antiplatelet therapy score in a large pooled cohort from 3 Japanese percutaneous coronary intervention studies. Circulation. 2018;137(6):551–562. doi:10.1161/CIRCULATIONAHA.117.028924
   PubMed Web of Science ®Google Scholar
• Song L, Guan C, Yan H, et al. Validation of contemporary risk scores in predicting coronary thrombotic events and major bleeding in patients with acute coronary syndrome after drug-eluting stent implantations. Catheter Cardiovasc Interv. 2018;91(S1):573–581. doi:10.1002/ccd.27468
   PubMedGoogle Scholar
• Ueda P, Jernberg T, James S, et al. External validation of the DAPT score in a nationwide population. J Am Coll Cardiol. 2018;72(10):1069–1078. doi:10.1016/j.jacc.2018.06.023
   PubMed Web of Science ®Google Scholar
• Witberg G, Zusman O, Bental T, et al. Validation of the DAPT score in real-world patients undergoing coronary stent implantation. Int J Cardiol. 2020;300:99–105. doi:10.1016/j.ijcard.2019.08.044
   PubMed Web of Science ®Google Scholar
• Puymirat E, Simon T, Cayla G, et al. Acute myocardial infarction: changes in patient characteristics, management, and 6-month outcomes over a period of 20 years in the FAST-MI program (French registry of acute ST-elevation or non-ST-elevation myocardial infarction) 1995 to 2015. Circulation. 2017;136(20):1908–1919. doi:10.1161/CIRCULATIONAHA.117.030798
   PubMed Web of Science ®Google Scholar
• Watanabe H, Domei T, Morimoto T, et al. Effect of 1-month dual antiplatelet therapy followed by clopidogrel vs 12-month dual antiplatelet therapy on cardiovascular and bleeding events in patients receiving PCI: the STOPDAPT-2 randomized clinical trial. JAMA. 2019;321(24):2414–2427. doi:10.1001/jama.2019.8145
   PubMed Web of Science ®Google Scholar
• Mehran R, Baber U, Sharma SK, et al. Ticagrelor with or without aspirin in high-risk patients after PCI. N Engl J Med. 2019;381(21):2032–2042. doi:10.1056/NEJMoa1908419
   PubMed Web of Science ®Google Scholar
• Vranckx P, Valgimigli M, Jüni P, et al. Ticagrelor plus aspirin for 1 month, followed by ticagrelor monotherapy for 23 months vs aspirin plus clopidogrel or ticagrelor for 12 months, followed by aspirin monotherapy for 12 months after implantation of a drug-eluting stent: a multicentre, open-label, randomised superiority trial. Lancet. 2018;392(10151):940–949. doi:10.1016/S0140-6736(18)31858-0
   PubMed Web of Science ®Google Scholar
• Fox KA, Carruthers KF, Dunbar DR, et al. Underestimated and under-recognized: the late consequences of acute coronary syndrome (GRACE UK-Belgian study). Eur Heart J. 2010;31(22):2755–2764. doi:10.1093/eurheartj/ehq326
   PubMed Web of Science ®Google Scholar
• Knuuti J, Wijns W, Saraste A, et al. 2019 ESC guidelines for the diagnosis and management of chronic coronary syndromes. Eur Heart J. 2020;41(3):407–477. doi:10.1093/eurheartj/ehz425
   PubMed Web of Science ®Google Scholar
• Würtz M, Olesen KKW, Mortensen MB, et al. Dual antithrombotic treatment in chronic coronary syndrome: European society of cardiology criteria vs. CHADS-P2A2RC score. Eur Heart J. 2022;43(10):996–1004. doi:10.1093/eurheartj/ehab785
   PubMed Web of Science ®Google Scholar
• Chichareon P, Modolo R, Kawashima H, et al. DAPT score and the impact of ticagrelor monotherapy during the second year after PCI. JACC Cardiovasc Interv. 2020;13(5):634–646. doi:10.1016/j.jcin.2019.12.018
   PubMed Web of Science ®Google Scholar
• Kereiakes DJ, Yeh RW, Massaro JM, et al. DAPT score utility for risk prediction in patients with or without previous myocardial infarction. J Am Coll Cardiol. 2016;67(21):2492–2502. doi:10.1016/j.jacc.2016.03.485
   PubMed Web of Science ®Google Scholar
• Dhawan J, Bray CL. Are Asian coronary arteries smaller than Caucasian? A study on angiographic coronary artery size estimation during life. Int J Cardiol. 1995;49(3):267–269. doi:10.1016/0167-5273(95)02315-N
   PubMed Web of Science ®Google Scholar
• Skowronski J, Cho I, Mintz GS, et al. Inter-ethnic differences in normal coronary anatomy between Caucasian (Polish) and Asian (Korean) populations. Eur J Radiol. 2020;130:109185. doi:10.1016/j.ejrad.2020.109185
   PubMed Web of Science ®Google Scholar
• Man C, Xiang S, Fan Y. Frailty for predicting all-cause mortality in elderly acute coronary syndrome patients: a meta-analysis. Ageing Res Rev. 2019;52:1–6. doi:10.1016/j.arr.2019.03.003
   PubMed Web of Science ®Google Scholar
• D’Ascenzo F, De Filippo O, Gallone G, et al. Machine learning-based prediction of adverse events following an acute coronary syndrome (PRAISE): a modelling study of pooled datasets. Lancet. 2021;397(10270):199–207. doi:10.1016/S0140-6736(20)32519-8
   PubMed Web of Science ®Google Scholar